 Positive results achieved in both GATHER1 and GATHER2 studies, whereby Zimura met prespecified primary endpoints of Mean rate of GA growth compared to sham control with statistical significance. NDA filing of Zimura for the treatment of patients with Geographic Atrophy are expected end of Q1 of 2023. 